BioCardia (NASDAQ:BCDA) announced on Tuesday that the U.S. Food and Drug Administration has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter.
The company is now scheduled for a substantive review and a formal meeting with the agency in early Q2 2026.
The review will be led by the Center for Devices and Radiological Health (CDRH) in close consultation with the Center for Biologics Evaluation and Research (CBER), reflecting the integrated nature of the device and the biological therapies it is designed to deliver.
The Helix system is a percutaneous catheter designed to deliver therapeutic agents into the heart muscle with a focus on precision and safety.
The CDRH’s involvement highlights the device's role in enabling BioCardia’s CardiAMP cell therapy, which currently holds a Breakthrough Designation from CBER for the treatment of ischemic heart failure.
This regulatory synchronization is intended to ensure that the delivery mechanism meets the rigorous standards required for minimally invasive intramyocardial procedures.
Management indicated that securing FDA clearance for the Helix catheter could provide a significant tailwind for the company's broader clinical portfolio.
By establishing the catheter as a cleared delivery platform, BioCardia aims to streamline the eventual approval process for the CardiAMP Cell Therapy.
This "device-first" strategy is designed to de-risk the regulatory pathway by validating the administration method independently of the cell-based treatment’s primary efficacy endpoints.
Financially, the progress comes as BioCardia continues to manage its capital to support its pivotal Phase 3 trials.
Leadership noted that the Helix platform’s potential to facilitate minimally invasive delivery addresses a major unmet need in the treatment of chronic heart failure, where traditional surgical interventions carry high risks.